Accepted for/Published in: JMIR Bioinformatics and Biotechnology
Date Submitted: Oct 29, 2022
Open Peer Review Period: Oct 29, 2022 - Dec 24, 2022
Date Accepted: Jun 8, 2023
(closed for review but you can still tweet)
Mutational Analysis of SARS-COV-2 Structural Proteins in Alpha, Beta, Gamma and Delta Variants using Bioinformatics tools
ABSTRACT
The novel SARS-COV-2 disease 2019 caused by new corona virus specie took a full swing within two to three months affecting social and economic platforms all around the world. One of the major reasons for the successful entry of SARS-CoV-2 into the human body is the similarity between the S protein of SARS-COV-2 and the ACE-2 receptor of Human cells. In this study, amino acid sequences of S protein (YP 009724390) and N protein (YP 009724397) from the reference sequence (NC 045512-Wu-2019) genome were compared to 133 isolated amino acid sequences of S and N proteins from the NCBI database. After data interpretation, a total of 143 non-synonymous mutations and 8 deletions were identified in S & N proteins. Combining the results of multiple sequence alignment & analyzing the amino acid substitutions, a set of new mutations like G72W, M2101I, L139F, 209-11deletion, G212S, P199L, P67S, I292T were observed which might be helpful in understanding the emergence of new variants as well as in development of new vaccines by targeting these mutated sites in future. Phylogenetic analysis of the same data indicated that either the evolutionary clade between the reference sequence and outgroups, was weakly supported or not supported at all.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.